How much has Medicare Part D spending on GLP-1 drugs grown since 2020?

How much has Medicare Part D spending on GLP-1 drugs grown since 2020?

Medicare Part D gross spending on GLP-1 drugs went from $7.22 billion in 2020 to $27.90 billion in 2024, about 3.9 times as much, summing the 13 GLP-1 brand rows in CMS’s Medicare Part D Spending by Drug data. CMS’s figures are before manufacturer rebates, which it does not publish.

All GLP-1 brands, by year

YearSpending, all GLP-1 brand rowsClaims, all GLP-1 brand rows
2020$7.22 billion6,018,487
2021$10.19 billion7,885,425
2022$14.21 billion10,406,887
2023$22.61 billion16,553,308
2024$27.90 billion22,164,471

By ingredient

Ingredient20202021202220232024
Semaglutide$1.53 billion$3.08 billion$5.60 billion$10.86 billion$15.16 billion
TirzepatideNo dataNo data$144.0 million$2.36 billion$6.34 billion
Liraglutide$1.90 billion$1.76 billion$1.56 billion$1.32 billion$329.0 million
Dulaglutide$3.28 billion$4.70 billion$6.23 billion$7.36 billion$5.45 billion
Exenatide$313.8 million$417.2 million$382.6 million$304.7 million$231.2 million
Insulin glargine and lixisenatide$121.4 million$165.6 million$215.9 million$303.0 million$300.2 million
Insulin degludec and liraglutide$71.9 million$75.8 million$78.0 million$91.4 million$91.3 million

By brand

OzempicSemaglutide$1,455,812,267$2,621,694,348$4,628,160,643$9,194,048,435$12,970,296,347
RybelsusSemaglutide$73,444,409$454,563,823$974,894,470$1,665,906,943$1,890,082,026
WegovySemaglutideNo dataNo dataNo data$199,774$301,283,291
MounjaroTirzepatideNo dataNo data$144,035,152$2,361,384,157$6,336,942,641
ZepboundTirzepatideNo dataNo dataNo dataNo data$387,343
Victoza 3-PakLiraglutide$1,545,815,415$1,422,292,583$1,238,594,872$1,004,635,145$203,063,050
Victoza 2-PakLiraglutide$349,476,159$334,897,957$319,205,509$317,213,565$77,832,721
LiraglutideLiraglutideNo dataNo dataNo dataNo data$48,095,824
TrulicityDulaglutide$3,284,873,062$4,702,174,724$6,225,291,668$7,363,856,224$5,454,134,725
Bydureon BciseExenatide Microspheres$266,160,951$379,243,467$355,078,758$284,056,759$215,354,678
ByettaExenatide$47,676,632$37,988,662$27,500,961$20,645,626$15,877,480
Soliqua 100-33Insulin Glargine/Lixisenatide$121,393,843$165,620,858$215,943,202$302,998,642$300,185,496
Xultophy 100-3.6Insulin Degludec/Liraglutide$71,921,892$75,755,898$77,994,459$91,415,961$91,255,682

CMS describes the Part D figures this way, in its catalog entry for the dataset:

“Drug spending metrics for Part D drugs are based on the gross drug cost, which represents total spending for the prescription claim, including Medicare, plan, and beneficiary payments.”

“The Part D spending metrics do not reflect any manufacturers’ rebates or other price concessions as CMS is prohibited from publicly disclosing such information.”

Spending changes with the number of people using a drug, the number of claims and the price per unit; CMS’s file reports each, and the brand table on the spending page shows claims and beneficiaries for 2024. This page does not say why spending changed.

Common questions

Which GLP-1 brand had the highest Part D spending in 2024?

Ozempic, at $12.97 billion in 2024, per CMS’s Medicare Part D Spending by Drug data.

Does CMS publish Part D spending for 2025 yet?

CMS’s Medicare Part D Spending by Drug file read Nov 15, 2026 covers 2020 to 2024.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.